PATENT CLAIM ANALYSIS

Application Number: 15773846
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "250000"]

Abstract:
In some embodiments, the invention relates to a BTK inhibitor or a pharmaceutically acceptable salt, cocrystal, ester, prodrug, solvate, hydrate or derivative thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to imidazopyrazine compounds, pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of a hyperproliferative disorder, an inflammatory disorder, an immune disorder, or an autoimmune disorder.

Claim (Index 1):
A compound of Formula (I) having the structure: or a pharmaceutically acceptable salt thereof, wherein: R 1  is hydrogen or methoxy, wherein methoxy is optionally substituted with one or two fluoro; X is: R 2  is hydrogen, halogen, methyl, methoxy, or ethoxy, wherein methyl, methoxy, and ethoxy are each optionally substituted with one, two, or three fluoro; Y is: R 3  is H or methyl.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 93.0
- Lexical Diversity: 2.11364
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15707508', '15758274', '15200875', '14762954', '11371180']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.774637110866478
- 35 USC 102 Novelty (BERT): 0.5341528589018492
- Combined Prediction Score: 0.7505886856700152
- Mean Citation Score: 325.567668
- Max Citation Score: 345.57678
- Similarity Product: 270.20615079244493

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test